NGS is a high-throughput, sensitive, specific, and relatively cost-efficient molecular test, and minimally invasive liquid biopsy is increasingly used in cancer treatment for genomic profiling. Using both measures has many advantages over other techniques. Profiling with NGS plus liquid biopsy has been shown to help detect cancer early, effectively identify actionable mutations, and help determine cancer patients' prognoses. With technical advances alongside reductions in cost, it is possible that using both NGS and liquid biopsy as biomarkers will be widely adopted into routine clinical diagnosis and oncogene-targeted treatment decisions.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: John C. Leighton Jr. Skill Checkup: A 53-Year-Old Woman With Dry Cough and a Lung Lesion - Medscape - Sep 01, 2022.